Strategic partnerships Leverage WhiteLab Genomics proven collaborations with Sanofi, Cytiva, Debiopharm, and strong academic ties to position as a preferred AI-driven genomic medicine partner for pharma, biotech, and research organizations seeking accelerated discovery and safer therapeutic design.

AI driven capabilities Highlight the proprietary AI platform for rational design of delivery systems and payload optimization to address partners’ needs in gene therapy vectors (viral and non-viral) and RNA/DNA payloads, offering a competitive edge in faster, safer preclinical development.

Expansion opportunities Target expansion into oncology, neurology, ophthalmology, auditory disorders, and rare diseases by aligning WhiteLab’s AI-enabled design capabilities with potential partner programs, especially those seeking AI-assisted indication discovery and vector optimization.

Global access Capitalize on offices in Paris, Boston, and Montréal to propose multinational collaboration models, enabling co-development across regions and access to diverse patient populations, academic partners, and regulatory landscapes.

Funding readiness Position WhiteLab as an attractive collaborator for funding-backed programs, emphasizing recent funding with a track record of growth, and outline co-development or milestone-based deals that align with investors’ and partners’ risk appetites.